ArticleNpj viruses2024
The anti-COVID-19 drug Paxlovid crosses biological barriers of the placenta and brain in rats.
Article in Npj viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paxlovid (nirmatrelvir plus ritonavir) is an orally available drug for the treatment of COVID-19 disease. However, limited information remains on the biological barrier transfer of nirmatrelvir. In the present study, we investigated whether nirmatrelvir crosses the blood-placenta barrier to reach the conceptus (the collective term for the fetus, placenta, and amniotic fluid) during pregnancy and the blood-brain barrier (BBB) in male rats. Additionally, in this study, gender and pregnancy issues were investigated. Multisite microdialysis coupled with validated UHPLC-MS/MS was developed to monitor nirmatrelvir levels in maternal blood and the conceptus in pregnant rats and of the blood and brain in male and nonpregnant female rats after administration of nirmatrelvir (15 mg/kg, i.v.) alone and nirmatrelvir (15 mg/kg, i.v.) combined with ritonavir (7 mg/kg, i.v.). Pharmacokinetic results showed that nirmatrelvir rapidly penetrates the blood-placenta barrier to reach the conceptus after administration of nirmatrelvir (15 mg/kg, i.v.) alone and nirmatrelvir (15 mg/kg, i.v.) combined with ritonavir (7 mg/kg, i.v.) in pregnant rats. Nirmatrelvir also crosses the BBB in male and nonpregnant female rats in the same dose regimen. Compared to sex and pregnancy factors, the results show that protein-unbound nirmatrelvir increased significantly during pregnancy and did not differ between nonpregnant female and male rats. The results indicated that the concentrations of nirmatrelvir in the blood, conceptus, and brain were higher than the effective concentration of 90% (total EC
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.